Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients

Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson's disease (PD), and orally bioavailable, brain penetrant and highly potent LRRK2 kinase inhibitors are in early stages of clinical testing. Detection of LRRK2 phosphorylation, as well as phosph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biochem J
Main Authors: Fernández, Belén, Lara Ordóñez, Antonio Jesús, Fdez, Elena, Mutez, Eugénie, Comptdaer, Thomas, Leghay, Coline, Kreisler, Alexandre, Simonin, Clémence, Vandewynckel, Laurine, Defebvre, Luc, Destée, Alain, Bleuse, Séverine, Taymans, Jean-Marc, Chartier-Harlin, Marie-Christine, Hilfiker, Sabine
Formato: Artigo
Idioma:Inglês
Publicado em: Portland Press Ltd. 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6792036/
https://ncbi.nlm.nih.gov/pubmed/31527116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BCJ20190315
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados